Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials

OBJECTIVE: To compare the relative efficacy of intravenous golimumab (GOL IV) and infliximab (IFX) for active ankylosing spondylitis (AS). METHODS: Propensity score (PS) methods were used to compare the efficacy of GOL IV 2 mg/kg and IFX 5 mg/kg using individual patient data (IPD) from the active ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Gensler, L. S., Chakravarty, S. D., Cameron, Chris, Peterson, S., Spin, P., Kafka, S., Nair, S., Deodhar, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497341/
https://www.ncbi.nlm.nih.gov/pubmed/32367407
http://dx.doi.org/10.1007/s10067-020-05051-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497341/
https://www.ncbi.nlm.nih.gov/pubmed/32367407
http://dx.doi.org/10.1007/s10067-020-05051-1

Ejemplares similares